image_alt_text
3

Andrew Wang, MD

AIMBE College of Fellows Class of 2019
For outstanding contributions in translating advances from nanomedicine and drug delivery research to improving cancer management and treatment.

Keeping immune cells in check to ward off diabetes

Via Advanced Science News | May 18, 2021

Researchers have shown they can avert the immune destruction of pancreatic beta cells and potentially halt the progression of type 1 diabetes. In autoimmune diseases, the body’s immune system mistakenly attacks itself, as it does foreign pathogens. In the case of type 1 diabetes, insulin-producing beta cells in the pancreas are the marked targets.

As a vital metabolic hormone, insulin is necessary for cells to take up glucose and use it as energy. To regulate this process, diabetics need to monitor their blood glucose levels constantly and inject the appropriate dose of insulin several times per day… Continue reading.

Dr. Andrew Wang Inducted into Medical and Biological Engineering Elite

Via AIMBE | March 28, 2019

WASHINGTON, D.C.—The American Institute for Medical and Biological Engineering (AIMBE) has announced the induction of Andrew Wang, MD, Associate Professor and Director of Clinical and Translational Research, Department of Radiation Oncology, University of North Carolina-Chapel Hill, to its College of Fellows.

Election to the AIMBE College of Fellows is among the highest professional distinctions accorded to a medical and biological engineer. The College of Fellows is comprised of the top two percent of medical and biological engineers. College membership honors those who have made outstanding contributions to “engineering and medicine research, practice, or education” and to “the pioneering of new and developing fields of technology, making major advancements in traditional fields of medical and biological engineering, or developing/implementing innovative approaches to bioengineering education.”

Dr. Wang was nominated, reviewed, and elected by peers and members of the College of Fellows for “outstanding contributions in translating advances from nanomedicine and drug delivery research to improving cancer management and treatment.”